Dr. Reddy's Laboratories defends against antitrust claims alleging "pay-for-delay" pharmaceutical patent settlement
Client(s) Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.
Jones Day is defending Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. against allegations that they violated antitrust and related laws through the settlement of Hatch-Waxman patent litigation. Dr. Reddy's manufactures memantine hydrochloride, a drug used in the treatment of Alzheimer's Disease and a generic alternative to the branded product, Namenda. The plaintiff, on behalf of a putative class of "End Payors," sued the brand manufacturer and a number of generics, including Dr. Reddy's. Plaintiff alleges that the brand and generic manufacturers had settled various Hatch-Waxman patent litigations through collusive "pay-for-delay" agreements, in violation of the rule set out by the Supreme Court in Federal Trade Commission v. Actavis. Plaintiff also alleges that the brand used the alleged delay in generic competition to effect a "product switch" -- the withdrawal of one product formulation in favor of a newer version, which is alleged to be an unlawful means of suppressing competition.
Sergeants Benevolent Association Health & Welfare Fund v. Actavis PLC, Case No. 1:15-cv-06549 (S.D.N.Y.)